Effect of Trisindolina-5 Compound on Cancer Stem Cell (CSC) Proliferation in-Vitro

Abstract

Cancer stem cells (CSCs) are a subset of cancer cells that have the abilities of normal stem cells. CSCs are cancer cell pioneers with self-renewal abilities that can cause CSCs to differentiate into several cancer cells. Because CSCs are resistant to conventional therapies, killing CSCs necessitates the use of a compound with powerful anticancer properties. Trisindoline has been shown to have powerful anticancer properties. Trisindoline has been synthesized into several modifications, the most recent of which is Trisindoline-5. The goal of this study is to find out what the IC50 value of Trisindoline-5 is. The cytotoxicity assay using Microculture Tetrazolium Technique Assay (MTT Assay) is used to determine IC50. The IC50 value of the Trisindoline-5 compound is 24.683 μM at 24 hours incubation, which classifies it as a medium cytotoxic compound, 17.067 μM at 48 hours incubation, which classifies it as a highly toxic compound, and 6497 μM at 72 hours incubation, which classifies it as a compound with no toxicity. While the IC50 value of doxorubicin is 1.611 μM after 24 hours, 2.334 μM after 48 hours, and 5.324 μM after 72 hours, it is classified as a compound with highly toxic activity.